Letter comments on: “Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’”

Detalles Bibliográficos
Autores principales: Müller, B., Estay, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092263/
https://www.ncbi.nlm.nih.gov/pubmed/35525185
http://dx.doi.org/10.1016/j.esmoop.2022.100487
_version_ 1784705106267078656
author Müller, B.
Estay, R.
author_facet Müller, B.
Estay, R.
author_sort Müller, B.
collection PubMed
description
format Online
Article
Text
id pubmed-9092263
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90922632022-05-12 Letter comments on: “Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’” Müller, B. Estay, R. ESMO Open Correspondence Elsevier 2022-05-04 /pmc/articles/PMC9092263/ /pubmed/35525185 http://dx.doi.org/10.1016/j.esmoop.2022.100487 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Correspondence
Müller, B.
Estay, R.
Letter comments on: “Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’”
title Letter comments on: “Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’”
title_full Letter comments on: “Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’”
title_fullStr Letter comments on: “Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’”
title_full_unstemmed Letter comments on: “Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’”
title_short Letter comments on: “Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’”
title_sort letter comments on: “twelve years of european cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’”
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092263/
https://www.ncbi.nlm.nih.gov/pubmed/35525185
http://dx.doi.org/10.1016/j.esmoop.2022.100487
work_keys_str_mv AT mullerb lettercommentsontwelveyearsofeuropeancancerdrugapprovalasystematicinvestigationofthemagnitudeofclinicalbenefit
AT estayr lettercommentsontwelveyearsofeuropeancancerdrugapprovalasystematicinvestigationofthemagnitudeofclinicalbenefit

Ejemplares similares